Plasma Metabolic Profiling of Mild Cognitive Impairment and Alzheimer's Disease Using Liquid Chromatography/Mass Spectrometry

Author(s): Ying Liu, Naijing Li, Ling Zhou, Qing Li, Wei Li

Journal Name: Central Nervous System Agents in Medicinal Chemistry
(Formerly Current Medicinal Chemistry - Central Nervous System Agents)

Volume 14 , Issue 2 , 2014

Become EABM
Become Reviewer

Graphical Abstract:


Objectives: Alzheimer’s disease (AD) is the main cause of gradual cognitive impairment in elderly individuals. This highlights the need of obtaining biomarkers to identify features that are different among mild cognitive impairment (MCI), AD and cognitively normal (CN) individuals. Design and methods: Ultra-performance liquid chromatography (UPLC)/mass spectrometry (MS) was employed to find the metabolic changes in plasma samples obtained from AD, MCI and CN individuals. Based on principal component analysis (PCA), the metabolic differences among AD, MCI and CN subjects were identified. Results: The PCA of UPLC/MS spectra indicated metabolic differences among AD, MCI and CN subjects. The peak intensities of progesterone, lysophos- phatidylcholines (LPCs), tryptophan, L-phenylalanine, dihydrosphingosine and phytosphingosine in the plasma of the MCI and AD subjects were significantly different from the CN subjects. Furthermore, the peak intensities of tryptophan, LPCs, dihydrosphingosine in the plasma of the AD subjects were significantly lower compared to the MCI subjects. Conclusion: Our data provide a link between metabolite imbalance and AD, and suggest that metabolomics can be used to reveal the early disease mechanisms occurred in the progression from CN to MCI and AD.

Keywords: Alzheimer's disease, UPLC-MS, mild cognitive impairment, dementia.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2014
Published on: 13 January, 2015
Page: [113 - 120]
Pages: 8
DOI: 10.2174/1871524915666141216161246
Price: $65

Article Metrics

PDF: 53